Immunogenicity of autoantigens [PDF]
BMC Genomics, 2011 Autoantibodies against self-antigens have been associated not only with autoimmune diseases, but also with cancer and are even found in healthy individuals. The mechanism causing the autoantibody response remains elusive for the majority of the immunogenic antigens. To deepen the understanding of autoantibody responses, we ask whether natural-occurring,
Eckart Meese +7 more
openaire +4 more sources
Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization [PDF]
Frontiers in Immunology, 2021 Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses. The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
Dana N. Thornlow +10 more
openaire +3 more sources
Immunogenicity of sulfatide [PDF]
Immunochemistry, 1977 Abstract The present study deals with the immunogenicity of sulfatide. Despite its acidic character, we succeeded in raising high titer antibodies. The most effective immunization procedure involved repeated intravenous injections of a mixture of sulfatide-lecithin-cholesterol-methylated bovibe serum albumin (1:4:10:10).
B. Zalc +7 more
openaire +4 more sources
Immunogenicity of biopharmaceuticals [PDF]
Nephrology Dialysis Transplantation, 2006 The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety of these agents is the potential for immunogenicity.
Huub Schellekens +2 more
openaire +2 more sources
A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration [PDF]
, 2014 Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery.
Castellino, Flora +9 more
core +1 more source
Immunogenicity of botulinum toxin [PDF]
Archives of Plastic Surgery, 2022 Botulinum toxin treatment is the most common non-surgical cosmetic treatment. Although there are many available treatments using botulinum toxin, their effects are temporary and repeated injections are required. These frequent injections can trigger an immunological response. In addition, botulinum toxin acts as an antigen in the body; thus, its effect
Syeo Young Wee, Eun Soo Park
openaire +3 more sources
Trastuzumab immunogenicity development in patients’ sera and in laboratory animals
BMC Immunology, 2021 Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany +3 more
doaj +1 more source
Comparative global immune-related gene profiling of somatic cells, human pluripotent stem cells and their derivatives: implication for human lymphocyte proliferation. [PDF]
, 2017 Human pluripotent stem cells (hPSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), represent potentially unlimited cell sources for clinical applications. Previous studies have suggested that hPSCs may benefit from immune privilege and
Allard, Patrick +12 more
core +1 more source
Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]
PLoS Computational Biology, 2013 T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis +7 more
doaj +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources